▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Jan 21, 2014 by Todd Campbell

What To Know About Questcor Pharmaceuticals' Most Important Drug

Questcor is building an eve- expanding franchise around its Acthar drug, including a new and potentially lucrative push into rheumatoid arthritis.

Jan 20, 2014 by Todd Campbell

Sirona Dental Systems, Inc. Sinks Its Teeth Into Rising Demand

After years of sluggish demand, an improving economy may mean sales growth for dentistry equipment makers Sirona (SIRO), Align (ALGN), 3M (MMM), and Danaher (DHR).

Jan 18, 2014 by Todd Campbell

AstraZeneca Plc: Big Pharma Checkup for 2014

A high profile patent loss for AstraZeneca's (AZN) Nexium this year creates big challenges for the company.

Jan 17, 2014 by Todd Campbell

Bayer's Challenge in 2014? For Xofigo to Win Share From Johnson & Johnson's Zytiga

The market for prostate cancer treatment is $12 billion and growing, but it's getting crowded. That makes this year important as Bayer's Xofigo faces off against Johnson's Zytiga and Medivation's Xtandit.

Jan 15, 2014 by Todd Campbell

Merck & Co, Inc.: Big Pharma Checkup for 2014

Merck (MRK) may be turning the corner from challenges tied to losing patent protection for Singulair. Here's what you need to know about the company in 2014.

Jan 15, 2014 by Todd Campbell

What You Need to Know About Accenture Plc's Winning the Healthcare.gov Contract

Accenture (ACN) has won the bidding battle to take over running the Affordable Care Act's insurance exchange this year. Here's what you can expect.

Jan 15, 2014 by Todd Campbell

Bristol-Myers Squibb Co.'s Daclatasvir May Prove a Winner

In the crowded market for treating hepatitis C, Bristol-Myers (BMY) may find a willing market for its promising drug daclatasvir.

Jan 14, 2014 by Todd Campbell

Flu Season Peaking? Here's What It Means for CVS Caremark Corporation, Walgreen Company, and Rite Aid Corporation

The CDC has reported cases of the flu are increasing. That should mean additional revenue friendly foot traffic for retail pharmacies CVS (CVS), Walgreen (WAG), and Rite-Aid (RAD).

Jan 14, 2014 by Todd Campbell

Jazz Pharmaceuticals Isn't Tired of Spending Money

Jazz just made another deal to strengthen its specialty drug franchise. Here's what you need to know.

Jan 13, 2014 by Todd Campbell

1 Year After the Spin-Off, Abbott Laboratories Looks Like a Winner

Strong and steady demand in key products. recent acquisitions, and lower costs provide plenty of opportunity for Abbott Laboratories (ABT).

Jan 13, 2014 by Todd Campbell

This is Why Sanofi Doubled Down on Alnylam

A $700 million purchase of 12% of Alnylam significantly expands Sanofi's ties to the company.

Jan 11, 2014 by Todd Campbell

Buying Discount Baby Formula? Another Win for Perrigo!

Perrigo (NYSE: PRGO) has been a big beneficiary of consumer's embrace of private label. That's a trend likely to continue as store brands win market share in more categories.

Jan 11, 2014 by Todd Campbell

Celgene's Bet on Epizyme Pays Off

Celgene and Epizyme got a big boost this week when Epizyme's EPZ-5676 met an important milestone.

Jan 10, 2014 by Todd Campbell

Pfizer Inc.: Big Pharma Checkup for 2014

Pfizer Inc.'s (PFE) cost cuts and newly approved drugs may position it for profit growth over the long haul.

Jan 9, 2014 by Todd Campbell

Eli Lilly & Co.: Big Pharma Checkup for 2014

The patent cliff hits Eli Lilly (LLY) hard in 2014. Here's how Lilly hopes to survive the sales headwind and compete against AstraZeneca (AZN), Novo Nordisk (NVO) and Sanofi (SNY)

Jan 9, 2014 by Todd Campbell

Align Technology, Inc.: The Best Medical Device Companies of 2013

Demand for Invisalign is going global and helping Align Technology (ALGN) challenge large competitors like 3M (MMM) and Danaher (DHR).

Jan 9, 2014 by Todd Campbell

NuVasive, Inc: The Best Medical Device Companies of 2013

Fewer complications and faster recovery times support demand for NuVasive's minimally invasive spine surgery products.

Jan 9, 2014 by Todd Campbell

Intercept Pharmaceuticals Inc.'s 270% Pop: Here's What You Need to Know

Data monitors halted the trial for Intercept's OCA drug for liver disease. This is what captured investors attention.

Jan 9, 2014 by Todd Campbell

Abiomed, Inc.: The Best Medical Device Companies of 2013

Abiomed's Impella heart pumps are carving out an important niche in cardiac cath labs.

Jan 7, 2014 by Todd Campbell

Cardiovascular Systems Inc.: The Best Medical Device Companies of 2013

A new coronary indication opens up a new market for Cardiovascular Systems' (CSII) devices with profit making implications.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services